Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7711 to 7725 of 8314 results

  1. Farco-fill Protect for indwelling urinary catheterisation (MIB121)

    July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.

  2. Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)

    This guidance has been replaced by NICE guideline NG17.

  3. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

    We have moved Diagnostics guidance 8 to become HealthTech guidance 315. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  4. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    We have moved Diagnostics guidance 9 to become HealthTech guidance 316. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  5. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    We have moved Diagnostics guidance 16 to become HealthTech guidance 360. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  6. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    We have moved Diagnostics guidance 13 to become HealthTech guidance 348. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  7. Use of our content for AI purposes

    Using NICE content for AI purposes. Includes complete content, adaptation, contextualisation, translation, selected extracts and the use of our COVID-19 content internationally.

  8. Antimicrobials evaluation panel members

    Read the biographies for all members of the NICE antimicrobial evaluation committee.

  9. Helping you put our guidance into practice

    Our system implementation team works with organisations to help to put our guidance into practice. We work with NHS, local authority and other organisations in their area, ensuring regular interaction with our stakeholders.

  10. Antimicrobials evaluation panel

    Details and meeting dates of the antimicrobials evaluation panel

  11. Get involved

    Tell us what matters to you, your organisation or your community.

  12. Public board meeting agendas and papers 2022

    Home About us Our board Public board meetings...

  13. Public board meeting agenda and papers: January 2022

    Agenda and papers of the NICE public board meeting on 19 January 2022

  14. Public board meeting agendas and papers 2023

    Home About us Our board Public board meetings...

  15. Public board meeting agenda and papers: March 2023

    Agenda and papers of the NICE public board meeting on 22 March 2023